ACE2 and neoplasm: The results showed that nearly a quarter of COVID-19 patients had gastrointestinal symptoms, that ACE2 expression was higher in the digestive tract than the lung, and the ratio of ACE2-positive cells in tumor tissues was higher than that in paracancerous normal tissue.